HER2-Low, HR-Positive, and Triple-Negative Breast Cancer: Expert Training and Real-world Perspectives on Novel HER2-Targeted and TROP-2–Targeted Therapies

This educational series will help healthcare professionals to effectively personalize the care of patients with breast cancer and will provide evidence-based expert perspectives on the implications of recent classification changes in HER2 expression levels, including discussions about TROP-2–targeted therapies for HER2-negative breast cancer with the aim to optimize treatment outcomes for patients with HER2-low, HR-positive, and triple-negative breast cancer. After the education, download the associated slidesets for use in the clinic.

Share

Program Content

Activities

HER2 Expression Spectrum: Module
Spectrum of HER2 Expression and Its Clinical Implications in Breast Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 08, 2024

Expires: January 07, 2025

HER2 Expression Spectrum: Slides
HER2 Expression in Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 08, 2024

Activities

HER2 Low Advanced BC: Module
Pushing the Boundaries of Unresectable or Metastatic HER2-Low Breast Cancer Treatment: New Insights and Innovations
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 26, 2024

Expires: January 25, 2025

HER2 Low Advanced BC: Slides
Pushing the Boundaries of Unresectable or Metastatic HER2-Low Breast Cancer Treatment: New Insights and Innovations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 26, 2024

Activities

Safety of ADCs in MBC: Module
Optimizing Outcomes and Quality of Life for Patients With Advanced Breast Cancer Through Effective Management of ADC-Associated Toxicities
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2024

Expires: February 06, 2025

Safety of ADCs in MBC: Slides
Optimizing Outcomes and Quality of Life for Patients With Advanced Breast Cancer Through Effective Management of ADC-Associated Toxicities
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2024

Activities

TROP2 Targeted Therapy: Module
TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 22, 2024

Expires: February 21, 2025

TROP2 Targeted Therapy: Slides
TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 22, 2024

Activities

Novel ADCs in Advanced Breast Cancer
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: March 20, 2024

Expires: March 19, 2025

Activities

Novel ADCs in Breast Cancer
Expert Perspectives on Novel and Emerging HER2-Directed and TROP-2‒Targeted ADCs for Advanced Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 02, 2024

Expires: May 01, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.